A Gentler Way to Give a Premature Baby's Lungs the Medicine They Need

What a large international study called OPTIMIST-A learned about giving surfactant through a thin tube instead of a breathing machine

Why a baby's first breaths can be so hard

When a baby is born many weeks early, the lungs are often the part of the body least ready for the outside world. Deep inside healthy lungs is a soapy, slippery substance called surfactant. It coats the millions of tiny air sacs and keeps them from collapsing each time the baby breathes out, the way a little soap keeps a bubble from popping. Babies born very early have not yet made enough surfactant, so their air sacs keep sticking shut. This is called respiratory distress syndrome, or RDS, and it makes every breath a struggle [1].

For many years, doctors learned that one of the gentlest ways to help these babies is a method called CPAP — continuous positive airway pressure. A soft set of prongs in the baby's nose blows a steady, gentle stream of air that holds the air sacs open, letting the baby keep breathing on its own. Large studies showed that starting with this gentle nose support, instead of immediately placing a breathing tube down the windpipe, is just as safe and sometimes better for the baby's lungs in the long run [2], [3].

The puzzle doctors needed to solve

CPAP creates a tricky problem, though. The best medicine for RDS is surfactant itself — doctors can give an artificial version straight into the lungs [4]. But the usual way to give it is through a breathing tube placed into the windpipe, and that same breathing tube and the machine attached to it can, over days and weeks, injure a premature baby's delicate lungs and lead to a chronic lung problem called bronchopulmonary dysplasia, or BPD [5]. So doctors were caught between two goods: give the helpful surfactant medicine, or avoid the breathing tube that can cause harm.

Some doctors came up with a clever middle path. Instead of placing a full breathing tube and connecting the baby to a machine, they would slip a very thin, soft tube briefly between the vocal cords, squirt the surfactant in while the baby kept breathing on CPAP, and then remove it. The baby gets the medicine without spending days on a ventilator. This approach is called minimally invasive surfactant therapy, or MIST [6], [7]. It seemed promising, but doctors needed a careful, fair experiment to know whether it truly helped.

How the study was done

That experiment was called OPTIMIST-A. It was a large, international study that took place at 33 newborn intensive care units in 11 countries [8]. The researchers enrolled 485 babies born between 25 and 28 weeks of pregnancy — very premature, as a full-term pregnancy is about 40 weeks. All of these babies were already on gentle nose CPAP but were starting to need extra oxygen, a sign their lungs were struggling [8].

To make the test as fair as possible, the babies were split into two groups purely by chance, like a coin toss. Half received surfactant through the thin tube. The other half received a carefully staged "pretend" procedure that looked and felt the same to the care team but gave no medicine [8]. This mattered because it meant the nurses and doctors could not tell which babies had been treated, so their hopes or expectations could not tip the results. Both groups followed the exact same rules for when a baby would need a full breathing tube if things got worse, so the only real difference between the groups was the early dose of surfactant [8].

What the researchers found

The study's main question was whether the thin-tube method would lower the combined chance of either dying early or developing chronic lung disease. On that single combined measure, the difference was not large enough to be certain: about 44 out of every 100 babies in the thin-tube group, compared with about 50 out of every 100 in the comparison group, had one of those outcomes [8]. Because that gap could have happened by chance, the researchers could not declare a clear win on the main question.

But when they looked more closely, a clearer picture emerged. Among the babies who survived, fewer of those who got the thin-tube surfactant developed chronic lung disease — about 37 out of 100, compared with about 45 out of 100 [8]. And the thin-tube method had some very clear, practical benefits. It roughly halved the number of babies who needed a breathing tube in the first three days of life, from about 72 out of 100 down to about 37 out of 100 [8]. It also roughly halved the chance of a collapsed lung — a painful, dangerous air leak — from about 10 out of 100 to under 5 out of 100 [8]. Fewer babies needed extra oxygen at home after they finally went home [8].

There was one finding that calls for honesty and care. Among the very youngest babies in the study, those born at 25 to 26 weeks, slightly more babies in the thin-tube group died, though the numbers were small and could have been due to chance [8]. The researchers were careful to say this should make doctors cautious about using the thin-tube method in the very tiniest, most fragile babies [8]. The procedure itself was safe overall: serious problems happened about equally often in both groups, and the doctors usually placed the thin tube successfully on the first try [8].

It can help to picture what the procedure involves, because parents sometimes see it or hear about it afterward. The whole thing is brief. A doctor gently looks into the baby's airway, passes the soft, thin tube just past the vocal cords, and gives the surfactant in a few small amounts over a short time while the baby keeps breathing on the nose support. During those moments, it is common and expected for the baby's heart rate to slow a little and the oxygen level to dip briefly before recovering [8]. The care team watches closely and is ready to give a few gentle puffs of air by mask if needed, which happened in only a small share of babies in the study [8]. Knowing in advance that a short wobble on the monitors is normal can make it far less frightening to witness.

What this means for families

If your baby is premature and the care team talks about giving surfactant through a thin tube, here is the heart of it. This method can often spare a baby from a breathing tube and a ventilator, and it lowers the risk of a collapsed lung. Among babies who survive, it lowered the rate of chronic lung disease. Those are real and valuable benefits. At the same time, the study did not prove that the method helps more babies survive overall, and it could not completely rule out a small risk for the very youngest babies [8]. So it is a helpful tool, but not a guaranteed life-saver, and good doctors will weigh it case by case — especially for the smallest infants.

It also helps to know that this medicine is given alongside other proven care, like a caffeine medicine that helps premature babies remember to breathe [9], and that international expert guidelines already support gentler ways of giving surfactant [10]. The success of the thin-tube method depends a lot on the skill and training of the team performing it, so it is offered in centers where staff have practiced the technique carefully [11]. If you are at a hospital that offers it, it is fair to ask your care team how often they use the method and how they decide whether it is right for your baby. There are no wrong questions, and a good team will welcome them and explain their thinking in plain terms.

What researchers are working on next

The most important questions now are about the long road ahead. Doctors very much want to know how these babies do not just at a few weeks of age, but as they grow into toddlers and children — how their lungs work and how they develop and learn [12]. Researchers are also studying whether the thin-tube method is truly better than simply placing a breathing tube briefly to give the same medicine and removing it quickly. And they are paying special attention to the smallest, earliest babies, to figure out who benefits most and who might need a different approach. For now, OPTIMIST-A offers families and doctors a clearer map: a gentler way to deliver a vital medicine, with honest information about both its real benefits and the questions that remain.

References

  1. Jobe AH. Why, when, and how to give surfactant. Pediatr Res. 2019;86(1):15–16. doi:10.1038/s41390-019-0372-1 ↩
  2. Committee on Fetus and Newborn; American Academy of Pediatrics. Respiratory support in preterm infants at birth. Pediatrics. 2014;133(1):171–174. doi:10.1542/peds.2013-3442 ↩
  3. Schmölzer GM, Kumar M, Pichler G, et al. Non-invasive versus invasive respiratory support in preterm infants at birth: systematic review and meta-analysis. BMJ. 2013;347:f5980. doi:10.1136/bmj.f5980 ↩
  4. Sweet DG, Carnielli V, Greisen G, et al. European consensus guidelines on the management of respiratory distress syndrome: 2019 update. Neonatology. 2019;115(4):432–450. doi:10.1159/000499361 ↩
  5. Thébaud B, Goss KN, Laughon M, et al. Bronchopulmonary dysplasia. Nat Rev Dis Primers. 2019;5(1):78. doi:10.1038/s41572-019-0127-7 ↩
  6. Kribs A, Pillekamp F, Hünseler C, et al. Early administration of surfactant in spontaneous breathing with nCPAP: feasibility and outcome in extremely premature infants. Paediatr Anaesth. 2007;17(4):364–369. doi:10.1111/j.1460-9592.2006.02126.x ↩
  7. Dargaville PA, Aiyappan A, Cornelius A, et al. Preliminary evaluation of a new technique of minimally invasive surfactant therapy. Arch Dis Child Fetal Neonatal Ed. 2011;96(4):F243–F248. doi:10.1136/adc.2010.192518 ↩
  8. Dargaville PA, Kamlin COF, Orsini F, et al. Effect of Minimally Invasive Surfactant Therapy vs Sham Treatment on Death or Bronchopulmonary Dysplasia in Preterm Infants With Respiratory Distress Syndrome: The OPTIMIST-A Randomized Clinical Trial. JAMA. 2021;326(24):2478–2487. doi:10.1001/jama.2021.21892 ↩
  9. Schmidt B, Roberts RS, Davis P, et al; Caffeine for Apnea of Prematurity Trial Group. Caffeine therapy for apnea of prematurity. N Engl J Med. 2006;354(20):2112–2121. doi:10.1056/NEJMoa054065 ↩
  10. Dargaville PA, Kamlin CO, De Paoli AG, et al. The OPTIMIST-A trial: evaluation of minimally-invasive surfactant therapy in preterm infants 25–28 weeks gestation. BMC Pediatr. 2014;14:213. doi:10.1186/1471-2431-14-213 ↩
  11. Vento M, Bohlin K, Herting E, et al. Surfactant administration via thin catheter: a practical guide. Neonatology. 2019;116(3):211–226. doi:10.1159/000502610 ↩
  12. Dargaville PA, Gerber A, Johansson S, et al; Australian and New Zealand Neonatal Network. Incidence and outcome of CPAP failure in preterm infants. Pediatrics. 2016;138(1):e20153985. doi:10.1542/peds.2015-3985 ↩